Table 2.
Persistence of Ebola virus glycoprotein circulating binding antibody response in children and adolescents.
| Study (age strata) |
Persistence time point analyzed | N | GMC (EU/mL) (95% CI) |
% Persisting response |
|
|---|---|---|---|---|---|
|
Phase 2
(Q2 Solutions) |
EBL2002 (BFA, CIV, KEN, UGA)
4–11 years |
1 year post-dose 1 (Day 365) |
53 |
638
(529; 767) |
98% |
|
EBL2002 (BFA, CIV, KEN, UGA)
12–17 years |
1 year post-dose 1 (Day 365) |
54 |
541
(433; 678) |
90% | |
|
EBL2004 (GNA, LIB, MAL, SL)
1–4 years |
1 year post-dose 1 (Day 365) |
105 |
1139
(905; 1432) |
100% | |
|
EBL2004 (GNA, LIB, MAL, SL)
5–11 years |
1 year post-dose 1 (Day 365) |
109 |
739
(585; 933) |
94% | |
|
EBL2004 (GNA, LIB, MAL, SL)
12–17 years |
1 year post-dose 1 (Day 365) |
127 |
731
(589; 907) |
77% | |
|
EBL2011 (SL)
1–3 years |
3.2 years post-dose 1 (Day 1168) |
27 |
934
(568; 1534) |
96% | |
|
EBL2011 (SL)
4–11 years |
3.2 years post-dose 1 (Day 1168) |
23 |
418
(287; 608) |
77% | |
|
Phase 3
(Q2 Solutions) |
EBL3001 (SL)
1–3 years |
1 year post-dose 1 (Day 360) |
120 |
750
(629; 894) |
96% |
|
EBL3001 (SL)
4–11 years |
1 year post-dose 1 (Day 360) |
123 |
436
(375; 506) |
71% | |
|
EBL3001 (SL)
12–17 years |
1 year post-dose 1 (Day 360) |
132 |
386
(326; 457) |
70% |
GMC, geometric mean concentration; EU/mL, enzyme-linked immunosorbent assay units per milliliter; CI, confidence interval; BFA, Burkina Faso; CIV, Côte d’Ivoire; KEN, Kenya; UGA, Uganda; GNA, Guinea; LIB, Liberia; MAL, Mali; SL, Sierra Leone; USA, United States of America.